
PHENYLBUTE - phenylbutazone injection

Clipper Distributing Company, LLC

For Horses Only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Phenylbutazone 20% Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties. Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:



BACKGROUND PHARMACOLOGY

Kuzell, ^{1, 2, 3} Payne, ⁴ Fleming, ⁵ and Denko ⁶ demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis and various other rheumatoid disorders in man. Anti-rheumatic and anti-inflammatory activity has been well established by Fabre, ⁷ Domenjoz, ⁸ Wilhelmi, ⁹ and Yourish. ¹⁰ Lieberman ¹¹ reported on the effective use of phenylbutazone in the treatment of painful conditions of the musculosketal system in dogs; including posterior paralysis associated with intervertebral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshua ¹² observed objective improvement without toxicity following long-term therapy of two aged arthritic dogs. Ogilvie and Sutter ¹³ reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculoskeletal weakness.

Camberos¹⁴ reported favorable results with phenylbutazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hock, arthritis of stifle and hip, arthrosis of the spine, chronic hip pains, achronic pain in the trapezius muscles, and generalized arthritis). Results were less favorable in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Sutter¹⁵ reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was limited to the third phalanx

INDICATIONS

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

CONTRAINDICATIONS

Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.

PRECAUTIONS

Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals of two weeks thereafter. Any significant fall in th total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

Store in refrigerator between 2° - 8°C (36° - 46°F)

DOSAGE AND ADMINISTRATION

HORSES

INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

GUIDELINES TO SUCCESSFUL THERAPY

- 1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
- 2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.
- 3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.

4. Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.

HOW SUPPLIED

INJECTABLE: For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL) Each mL contians 200 mg of phenylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection, Q.S.

REFERENCES

- 1. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.
- 2. Kuzell, W.C., Schaffarzick, R.W., Brown, B. and Mankle, E.A.: Jour. Amer. Med. Assoc. 149:729, 1952.
- 3. Kuzell, W.C., Schaffarzick, R.W., Calif. Med. 777:319, 1952.
- 4. Payne, R.W., Shetlar, M.R., Farr, C., Hellbaum, A.A., and Ishmael, W.K.T.: J.Lab. Clin. Med. 45:331, 1955.
- 5. Fleming, J. and @Will, G.: Ann Rheumat. Dis. 12:95, 1953.
- 6. Denko, C.W., and Rumi, D.: Amer. Practit. 6:1865, 1955.
- 7. Fabre, J. and Berger, A.: Semaine Hop. (Paris) 31:87, 1955.
- 8. Domenjoz, R., Theobald, W. and Morsdorf, K., Arzneimittel-Forsch. 5:488, 1955.
- 9 Wilhelmi, G., and Pulver, R.: Arzneimittel-Forsch. 5:221, 1955.
- 10. Yoursh, N., Paton, B., Brodie, B.B and Burns, J.J.: AMA Arch. Ophth. 53:264, 1955.
- 11. Lieberman, L.L.: Jour. Amer. Vet. Med. Assoc. 125:128, 1954.
- 12. Joshua, J.O.: Vet. Rec. 68:60 (Jan 21), 1956.
- 13. Ogilvie, F.B. and Sutter, M.D.: Vet. Med 52:492-494, 1957.
- 14. Camberos, H.R.: Rev. Med. Vet. (Buenos Aires); 38:9, 1956.
- 15. Sutter, M.F.: Vet Med. 53:83 (Feb.), 1958.

INDICATIONS

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

Intravenous dosage (not subcutaneous or intramuscular use):

Horses: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.

Not for use in Horses intended for food.

See package outsert for additional information.

ANADA 200-371, Approved by FDA

Each mL contains:

FOR HORSES ONLY

KEEP OUT OF REACH OF CHILDREN

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



Kuzell, W.C., Schaffarzick, R.W., Naugler, W.G., and Mankle, E.A.: AMA Arch. Int. Med. 92:646, 1953.

2. Kuzell, W.C., Schaffarzick, R.W., Brown, B. and Manide, E.A.:

- Kurel, W.L., Schaffarrick, H.W., Brown, B. and Manile, E.A.: Jour, Amer. McA. 4800. 1897:29, 1952.
 Kuzell, W.C., Schaffarrick, R.W., Calif, Med. 77-319, 1952.
 A. Luzell, W.C., Schaffarrick, R.W., Calif, Med. 45:331, 1955.
 Fleming, J. and Will, G. Amer Rheumat, Dis. 1295, 1963.
 Denko, C.W., and Rumi, D.: Amer. Practs. 6:1885, 1955.

- Fabre, J. and Berger, A: Semaine Hop. (Paris) 31:87, 1955.
 Domenjoz, R., Theobald, W. and Morsdorf, K.; Arzneimittel Forsch, 5:488, 1955.
- Forsch, \$4:68, 1995.

 Willhelmi, G., and Pulver, R.: Arzneimittel-Forsch, 5:221, 1955.

 10. Yourish, N., Paton, B., Brodie, B.B. and Burne, J.J.: AMA
 Arch. Ophth, \$3:254, 1955.

 11. Lieberman, L.L.: Jour, Armet, Vet. Med. 43:200, 125:128, 1954.

 12. Joehum, J.O.: Vet. Rec. 8890 (Jan. 21), 1956.

 13. Ogilvie, F.B. and Sutter, M.D.: Vet. Med. 52:482-494, 1957.

- Camberos, H.R.: Rev. Med. Vet. (Buenos Aires); 38.9, 1956.
 Sutter, M.D.: Vet. Med. 53:83 (Feb.), 1958.

7

INDICATIONS: For relief of inflammatory conditions associated with the musculoskeletal system in horses.

Intravenous dosage (not for subcutaneous or intramuscular use):

Horses: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.

Not for use in Horses intended for food. See package outsert for additional information.

> ANADA 200-371, Approved by FDA Sparhawk Laboratories, Inc. Lenexa, KS 66215, USA

Trademarks are property of Clipper Distributing Company, LLC

Rev. 06-10

P-4825-04

Phenylbute® Injection 20% (Phenylbutazone)

For Horses Only

CAUTION: Faderal law restricts this drug to use by
OAUTION: Faderal law restricts this drug to use by
or on the order of a licensed veterinarian.
DESCRIPTION: Phenylbutza Injection 20% (phenylbutzzone) is a synthetic, nonhormonal anti-inflammatory,
antipyretic compound useful in the management of
inflammatory conditions. The apparent analgesic
anti-inflammatory properties.
Chemically, phenylbutzaone is 4-butyl-1_2-(ip)henyl3_5-pyrazolidinedione. It is a pyrazolon derivative
entriety unrelated to the steroid hormones, and has
the following structural formula:

BACKGROUND PHARMACOLOGY: Kuzell, 1,2,3
Payne, 4 Flaming, 5 and Denko 6 demonstrated clinical effectiveness of phenylbutazone in acute rheumatism, gout, gouty arthritis, and various other rheumatoid disorders in man. Anti-rheumatic other rhounatoid disorders in man. Anti-rhounatic and anti-inflammatory activity has been well established by Fabre, Domenios, 8 Wilhelmi, 9 and Yourish. 10 Lieberman 11 reported on the effective use of phenylbutazone in the trestment of peinful conditions of the musculoskeletal system in dogs; including posterior paralysis associated with intervertebral disc syndrome, painful fractures, arthritis, and painful injuries to the limbs and joints. Joshus 3 doserved objective improvement without toxicity following long-term therapy of two aged arthritis dogs. Oglivis and Sutter 13 reported rapid response to phenylbutazone therapy in a review of 19 clinical cases including posterior paralysis, posterior weakness, arthritis, rheumatism, and other conditions associated with lameness and musculoskejetal weakness. musculoskeletal weakness. Camberos¹⁴ reported favorable results with

2

dication. If long-term therapy is planned, oral

administration is suggested.

4. Many chronic conditions will respond to phenyl-butazone therapy, but discontinuance of treatment

HOW SUPPLIED INJECTABLE: For Horses only: 100 mL vials, 200 mg/mL (1 g/5 mL) Each mL contains 200 mg of phanylbutazone, 10.45 mg of benzyl alcohol as preservative, sodium hydroxide to adjust pH to 9.5 to 10.0, and water for injection, O.S.

may result in recurrence of symptoms

HOW SUPPLIED

nenylbutazone following intermittent treatment of Thoroughbred horses for arthritis and chronic arthrosis (e.g., osteoarthritis of medial and distal bones of the hock, arthritis of stifle and hip, bones of the hock, arthritis of stiffle and hip, arthrosis of the spine, chronic hip pains, chronic pain in trapezius muscles, and generalized arthritis. Results were less favorable in cases of traumatism, muscler upture, strains and inflammations of the third phalanx. Sutter 15 reported favorable response in chronic equine arthritis, fair results in a severely bruised mare, and poor results in two cases where the condition was ligited to the bride phalanx. limited to the third phalanx

INDICATIONS: For relief of inflammatory conditions ociated with the musculoskeletal system in

norses.

CONTRAINDICATIONS: Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.

PRECAUTIONS: Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of counter measures. In the treatment of inflammatory conditions associated with infections,

specific anti-infective therapy is required. Store in a refrigerator between 2°C - 8°C (36°F - 46°F).

4

DOSAGE AND ADMINISTRATIONS

HORSES INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit Intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone doseae forms.

- dosage forms.

 GUBELINES TO SUCCESSFUL THERAPY

 1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.

 2. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant colinical response is evident fafer 5 days, reevaluate disgnosis and therapeutic approach.
- diagnosis and therapeutic approach.

 3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous

6

5

3